Centessa Pharmaceuticals plc (CNTA)
| Market Cap | 6.13B +257.9% |
| Revenue (ttm) | n/a |
| Net Income | -250.64M |
| EPS | -1.78 |
| Shares Out | 154.73M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,702,171 |
| Open | 39.76 |
| Previous Close | 39.80 |
| Day's Range | 39.62 - 39.81 |
| 52-Week Range | 10.95 - 40.26 |
| Beta | 1.12 |
| Analysts | Buy |
| Price Target | 44.57 (+12.49%) |
| Earnings Date | May 5, 2026 |
About CNTA
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for CNTA stock is "Buy." The 12-month stock price target is $44.57, which is an increase of 12.49% from the latest price.
News
Centessa gets FDA orphan drug designation for cleminorexton
Centessa (CNTA) Pharmaceuticals’ cleminorexton was granted FDA orphan designation as a treatment of idiopathic hypersomnia, according to a post to the agency’s website.
Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development
Proven Chief Medical Officer at several publicly listed and clinical-stage oncology companies with successful track record developing multiple modalities including radiotherapies from preclinical thro...
Centessa Pharmaceuticals Proxy statement: Proxy filing
Centessa Pharmaceuticals filed a proxy statement on May 7, 2026, providing details for shareholder voting and corporate governance matters.
Centessa Pharmaceuticals Quarterly report: Q1 2026
Centessa Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 5, 2026.
Centessa Pharmaceuticals Proxy statement: Proxy filing
Centessa Pharmaceuticals filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Centessa downgraded to Equal Weight from Overweight at Wells Fargo
Wells Fargo downgraded Centessa (CNTA) to Equal Weight from Overweight with a $42 price target after after Eli Lilly (LLY) announced an agreement to acquire the company for $38 per…
Centessa Pharmaceuticals Proxy statement: Proxy filing
Centessa Pharmaceuticals filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
Centessa Pharmaceuticals Proxy statement: Proxy filing
Centessa Pharmaceuticals filed a proxy statement on April 13, 2026, providing details for shareholder voting and corporate governance matters.
Centessa downgraded to Hold from Buy at Truist
Truist analyst Danielle Brill downgraded Centessa (CNTA) to Hold from Buy with a $38 price target after Eli Lilly (LLY) announced an agreement to acquire the company for $38 per…
Centessa downgraded to Neutral from Buy at Guggenheim
Guggenheim analyst Debjit Chattopadhyay downgraded Centessa (CNTA) to Neutral from Buy after Eli Lilly (LLY) announced an agreement to acquire the company for $38 per share in cash plus a…
Centessa downgraded to Market Perform from Outperform at LifeSci Capital
LifeSci Capital downgraded Centessa (CNTA) to Market Perform from Outperform after Eli Lilly (LLY) announced an agreement to acquire the company for $38 per share in cash plus a non-transferable…
Centessa downgraded to Market Perform from Outperform at Leerink
Leerink downgraded Centessa (CNTA) to Market Perform from Outperform with a $40 price target after Eli Lilly (LLY) announced an agreement to acquire the company for $38 per share in…
Nxera Pharma's Partner Centessa Pharmaceuticals to be Acquired by Lilly
Tokyo, Japan and Cambridge, UK, 1 April 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that its partner, Centessa Pharmaceuticals Limited (“Centessa”), has announced that...
Alkermes jumps 15% on renewed biotech M&A buzz, says Leerink
Alkermes (ALKS) rose 15% after Eli Lilly (LLY) agreed to acquire Centessa Pharmaceuticals (CNTA), reflecting renewed M&A momentum in biotech, Leerink tells investors in a research note. While the boos...
Centessa acquisition ‘may help rouse’ Alkermes shares, says RBC Capital
After Eli Lilly (LLY) announced the intent to acquire Centessa (CNTA) for $6.3B in cash plus an additional $1.5B split across 3 contingent value rights, RBC Capital said the deal…
Eli Lilly stock rises after $7.8B Centessa deal—bet on sleep drugs
Eli Lilly has agreed to acquire Centessa Pharmaceuticals in a deal valued at up to $7.8 billion, marking a significant expansion of the drugmaker's neuroscience portfolio into sleep medicine. Under th...
Alkermes jumps after Eli Lilly acquires peer Centessa
Shares of Alkermes (ALKS) ALKS) are moving higher after Eli Lilly (LLY) reached an agreement to acquire Centessa (CNTA) for up to $7.8B. Alkermes, like Centessa, is developing an orexin…
Centessa downgraded to Peer Perform from Outperform at Wolfe Research
Wolfe Research downgraded Centessa (CNTA) to Peer Perform from Outperform following the announcement of Eli Lilly’s (LLY) acquisition agreement. The firm believes Centessa has a “very good chance to h...
Lilly to spend up to $7.8 billion to acquire Centessa, a maker of experimental sleep disorder drugs
Eli Lilly will pay up to $7.8 billion to acquire Centessa Pharmaceuticals. Centessa is developing orexin agonists to treat narcolepsy and excessive drowsiness.
Centessa downgraded to Neutral from Buy at B. Riley
B. Riley analyst Mayank Mamtani downgraded Centessa (CNTA) to Neutral from Buy with a $45 price target after Eli Lilly (LLY) announced an agreement to acquire the company for $38…
Why Eli Lilly Is Buying Centessa for $7.8 Billion
Bloomberg Intelligence's Sam Fazeli discusses Eli Lilly's $7.8 billion acquisition of Centessa, marking the company's entry into the sleep disorder drug market. He speaks on "Bloomberg Open Interest.
Centessa Pharmaceuticals Proxy statement: Proxy filing
Centessa Pharmaceuticals filed a proxy statement on March 31, 2026, providing details for shareholder voting and corporate governance matters.
Centessa Pharmaceuticals Proxy statement: Proxy filing
Centessa Pharmaceuticals filed a proxy statement on March 31, 2026, providing details for shareholder voting and corporate governance matters.